Rafael (NYSE:RFL) Rating Lowered to Sell at Wall Street Zen

Rafael (NYSE:RFL) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Rafael Stock Up 3.6%

Shares of NYSE RFL opened at $1.75 on Friday. Rafael has a 52-week low of $1.28 and a 52-week high of $3.19. The stock has a market capitalization of $61.41 million, a P/E ratio of -1.86 and a beta of 0.99. The firm’s 50-day moving average price is $1.86 and its two-hundred day moving average price is $1.83.

Rafael (NYSE:RFL) last posted its quarterly earnings data on Wednesday, June 11th. The company reported ($0.19) EPS for the quarter. The firm had revenue of $0.36 million during the quarter. Rafael had a negative return on equity of 24.75% and a negative net margin of 3,127.60%.

Insider Buying and Selling

In other news, CEO Howard S. Jonas bought 13,080,457 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were acquired at an average cost of $1.28 per share, for a total transaction of $16,742,984.96. Following the purchase, the chief executive officer owned 12,299,207 shares of the company’s stock, valued at $15,742,984.96. This represents a -1,674.30% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 10.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Rafael

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in Rafael by 17.9% in the fourth quarter. Geode Capital Management LLC now owns 174,561 shares of the company’s stock worth $288,000 after purchasing an additional 26,493 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Rafael during the first quarter worth about $26,000. Finally, Ieq Capital LLC bought a new position in Rafael in the first quarter valued at approximately $447,000. Institutional investors own 11.30% of the company’s stock.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.